The potential for ischemic preconditioning to reduce infarct size was first recognized more
than 30 years ago [180]. Despite extension of the concept to ischemic postcondition‑ing …

Disturbances in cardiac metabolism underlie most cardiovascular diseases. Metabolomics,
one of the newer omics technologies, has emerged as a powerful tool for defining changes …

Despite the enhanced knowledge of the pathophysiology of heart failure (HF), it still remains
a serious syndrome with substantial morbidity, mortality, and frequent hospitalizations …

The complex pathobiology underlying cardiovascular diseases (CVDs) has yet to be
explained. Aberrant epigenetic changes may result from alterations in enzymatic activities …

This article provides an update regarding the most recent published literature on galectin-3
as a biomarker in heart failure (HF) and gives an outlook toward its use as a biotarget. 1 In …

Trimethylamine (TMA) and its N-oxide (TMAO) are ubiquitous in prokaryote and eukaryote
organisms as well as in the environment, reflecting their fundamental importance in …

Lipids represent a valuable target for metabolomic studies since altered lipid metabolism is
known to drive the pathological changes in cardiovascular disease (CVD). Metabolomic …

Background Diabetes mellitus (DM) and coronary artery disease (CAD) constitute inter-
related clinical entities. Biomarker profiling emerges as a promising tool for the early …

Background Incidence rates of cardiovascular disease (CVD) are increasing, partly driven
by the diabetes epidemic. Novel prediction tools and modifiable treatment targets are …

Precision medicine promises to dramatically improve patient outcomes and reduce health
care costs through a shift in focus from disease treatment to prevention and individualized …